Skip to main content

Table 1 Features of various IL-6 inhibitors—available and investigational, [in RA]

From: Interleukin-6 inhibition in the management of non-infectious uveitis and beyond

 

Target

Structure

Dose and route of administration

Current indications (FDA approved)

Potential indications

Tocilizumab

sIL-6R mIL-6R

Recombinant humanized

4–8 mg/kg IV q4wk

162 mg SC q2wk/q4wk

RA, JIA, GCA

Takayasu’s arteritis, Behçet’s disease, adult onset Still’s disease, multicentric Castleman’s disease (approved in Japan), relapsing polychondritis, Cogan’s disease, inflammatory myositis, lupus, NIU

Sarilumab

sIL-6R mIL-6R

Human mAb

200 mg SC q2wk

RA

RA, NIU

Sirukumab

IL-6

Human mAb

FDA approval denied for RA

n/a

Siltuximab

IL-6

Chimeric

12 mg/kg

q3wk

Castleman’s disease

Multiple myeloma, currently no studies in NIU

Clazakizumab

IL-6

Humanized mAb

25–200 mg SC q4wk

Not FDA approved

Renal transplant, psoriatic arthritis, RA

Olokizumab

IL-6

Humanized mAb

64 mg SC q2wk/q4wk

Not FDA approved

RA

ALX-0061

sIL-6R mIL-6R

Nanobody (heavy chain-only)

n/a

Not FDA approved

SLE, RA

MEDI 5117

IL-6

Human mAb

n/a

Not FDA approved

  1. RA rheumatoid arthritis, JIA juvenile idiopathic arthritis, GCA giant cell arteritis, NIU non-infectious uveitis, SC subcutaneous, IV intravenous, n/a not available, qnwk once every “n” number of weeks